Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study

Anaplastic lymphoma kinase (ALK) test in advanced non-small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring ALK gene rearrangement. This study aimed to investigate the real-world test patterns and positive rates of ALK gene rearrangements in advanced NSCLC.